Risk Factor Control Before Orthopedic Surgery (OPTMIZE-OS)
Optimization of Pre-surgical Testing With an Intensive Multifactorial Intervention to MinimiZe Cardiovascular Events in Orthopedic Surgery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10003
- NYU Hospital for Joint Diseases
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
• ≥ 21 years of age
- Subjects undergoing open orthopedic surgery of the hip, knee or spine
- Surgery is scheduled at least 3 days after PAT visit and no more than 14 days.
High risk subject cohort
- Coronary artery disease, or
- Cerebrovascular disease (prior stroke, TIA or carotid artery disease (>70% stenosis), or
- Peripheral artery disease, or
- Prior Venous thromboembolism or arterial thromboembolism, or
- Age ≥ 60 years and 2 of the following
- Renal insufficiency (creatinine clearance < 60ml/min)
- Diabetes
- COPD
- Hypertension
- Active smoker or stopped less than 30 days prior to consent
- Cancer (excluding BCC)
- Heart Failure
Exclusion Criteria:
• Known intolerance to statins
- Subject is already on maximum dose statin (atorvastatin/Lipitor 80mg daily or rosuvastatin/crestor 40mg daily)
- Bilateral renal artery stenosis
- End stage renal disease (receiving dialysis or CrCl <30ml/min)
- Known allergy or intolerance to ACE-inhibitor (other than cough) or Angiotensin receptor blocker (e.g. angioedema, hyperkalemia)
- Known allergy or intolerance to beta blockers
- Known sick sinus syndrome not treated with permanent pacemaker
- Known greater than first degree AV block not treated with a pacemaker
- Excessive alcohol intake
- Acute Coronary Syndrome requiring hospitalization within 1 month
- Stroke within 1 month
- Known pregnancy
- Severe co-morbid condition with life expectancy < 6 months
- Inability to give informed consent or adhere to follow-up as per protocol
- Current participation in another investigational drug or device trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: Control
Standard of care
|
|
|
Active Comparator: Treatment
Lifestyle counseling (nutrition, physical activity, medication compliance and smoking cessation) Atorvastatin 80mg PO QD Metoprolol 25mg PO BID if HR is elevated Lisinopril 2.5 mg PO QD if SBP is elevated
|
25mg PO BID if the HR is elevated at preadmission testing
Other Names:
2.5mg PO QD if the HR is elevated at preadmission testing
Other Names:
80mg PO QD at preadmission testing
Other Names:
Diet, exercise, medication adherance and smoking counseling
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of Partipants That Experienced Death, Myocardial Infarction, Stroke, Transient Ischemic Attack, Myocardial Necrosis, or Venous Thromboembolism
Time Frame: 30 days
|
30 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Modified Composite of Cardiovascular Events
Time Frame: 30 days
|
the reduction in the composite of death, myocardial infarction, stroke, transient ischemic attack, myocardial necrosis, venous thromboembolism, or reoperation
|
30 days
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Length of Stay
Time Frame: Hospital stay, ~7 days
|
Hospital stay, ~7 days
|
|
Each Individual Endpoint of the Composite of Cardiovascular Events
Time Frame: 30 days
|
30 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jeffrey Berger, MD, NYU School of Medicine
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Antimetabolites
- Protease Inhibitors
- Protective Agents
- Cardiotonic Agents
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Sympatholytics
- Adrenergic beta-1 Receptor Antagonists
- Atorvastatin
- Metoprolol
- Lisinopril
- Angiotensin-Converting Enzyme Inhibitors
Other Study ID Numbers
Other Study ID Numbers
- 12-02407
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.